

मिसिलस.- 8(131)/2025/डी.पी/एनपीपीए-डीवी-II
F. No. 8(131)/2025/DP/NPPA-Div. II

कार्यवाहीस. : 263/131/2025/F

Proceeding No: 263/131/2025/F

Minutes of the 263rd (overall) and 131st meeting of the Authority under DPCO, 2013 held on 25.3.2025 at 11.30 A.M.

The 263rd meeting of the Authority (overall), which is the 131st meeting under the DPCO, 2013 was held on 25th March, 2025 at 11.30 A.M. under the Chairmanship of Shri P. Krishnamurthi, Chairman, NPPA. The following Authority members were present during the meeting:

- (i) Dr. Vinod Kotwal, Member Secretary, NPPA
- (ii) Manmohan Sachdeva, Additional Chief Adviser Cost (ACAC), O/o Chief Adviser (Cost), Department of Expenditure
- (iii) Shri Antony Cyriac, Economic Advisor, Department of Economic Affairs

Shri Ranga Chandrashekar, Joint Drug Controller, CDSCO, Ministry of Health & Family Welfare.

The following officers of NPPA attended the meeting and assisted the Authority in its deliberations:

- (i) Shri Sanjay Kumar, Advisor (Cost)
- (ii) Shri G.L. Gupta, Director (M&E)
- (iii) Ms. Rashmi Tahiliani, Director (Pricing)
- (iv) Shri Mahaveer Saini, Deputy Director (Pricing)
- (v) Ms. Yuvika Panwar, Assistant Director (Pricing)

1. Agenda item no. 1 - Confirmation of Minutes of the 130th Meeting held on 25.2.2025.

- 1.1 The Authority confirmed the minutes of the meeting without any change.

2. Agenda item no. 2 - Action Taken Report (ATR) on decisions taken by NPPA in its 130th Meeting held on 25.2.2025.

- 2.1 Noted.

3. Agenda item no. 3 - Status of New Drug applications

- 3.1 Noted.

4. Agenda item no. 4 – New Drug applications for Price fixation under Para 5 and Para 15 of DPCO, 2013

4.1 The Authority deliberated on 80 (Eighty) cases of retail price fixation of new drugs as presented in Agenda no. 4 (i) to 4 (lxxx) falling under the purview of Para 2(1)(u) of DPCO, 2013. The Authority approved the retail prices of 80 (Eighty) new drugs under Para 5 and 15 of the DPCO 2013 as given in **Table 1 below:**

Table No. 1: Retail price fixation of new drugs

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	4(i)	Aspirin Gastro-resistant & Rosuvastatin Capsules	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (as film coated Rosuvastatin tablets IP) Aspirin IP 75mg (as Aspirin Gastro-Resistant tablets IP)	1 Capsule	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Micro Labs Ltd.	10.73
2	4(ii)	Atorvastatin & Clopidogrel Tablets	Each uncoated bilayered tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 10 mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Torrent Pharmaceuticals Ltd.	14.02
3	4(iii)	Atorvastatin & Clopidogrel Tablets	Each uncoated bilayered tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 20 mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Torrent Pharmaceuticals Ltd.	18.76
4	4(iv)	Atorvastatin & Clopidogrel Tablets	Each uncoated bilayered tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40 mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Torrent Pharmaceuticals Ltd.	25.61

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
5	4(v)	Atorvastatin & Clopidogrel Tablets	Each uncoated bilayered tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40 mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Micro Labs Ltd.	25.61
6	4(vi)	Atorvastatin & Ezetimibe Tablets	Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 10 mg Ezetimibe IP 10 mg	1 Tablet	M/s Micro Labs Ltd.	19.40
7	4(vii)	Atorvastatin & Ezetimibe Tablets	Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 20 mg Ezetimibe IP 10 mg	1 Tablet	M/s Mascot Health Series Pvt. Ltd./ M/s Micro Labs Ltd.	27.68
8	4(viii)	Atorvastatin & Ezetimibe Tablets	Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40 mg Ezetimibe IP 10 mg	1 Tablet	M/s Mascot Health Series Pvt. Ltd./ M/s Micro Labs Ltd.	30.47
9	4(ix)	Atorvastatin Calcium & Fenofibrate Tablets	Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 10 mg Fenofibrate IP 160 mg	1 Tablet	M/s BRD MediLabs (Unit-II)/ M/s Troikaa Pharmaceuticals Ltd.	15.91
10	4(x)	Bisoprolol Fumarate & Telmisartan Tablets	Each film coated tablet contains: Bisoprolol Fumarate IP 2.5 mg Telmisartan IP 40 mg	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd.	10.28
11	4(xi)	Bisoprolol Fumarate & Telmisartan Tablets	Each film coated tablet contains: Bisoprolol Fumarate IP 5 mg Telmisartan IP 40 mg	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd.	11.92
12	4(xii)	Calcium Citrate, Vitamin D3,	Each film coated tablet contains: Calcium Citrate USP	1 Tablet	M/s Mascot Health Series Pvt. Ltd./	14.69

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
		Methylcobalamin, Pyridoxine HCl & Folic Acid Tablets	1000 mg Vitamin D3 IP 200 IU Methylcobalamin IP 500 mcg Pyridoxine HCl IP 10 mg Folic Acid IP 5 mg		M/s Mankind Pharma Ltd.	
13	4(xiii)	Ceftriaxone, Disodium Edetate & Sodium powder for solution for infusion	Each vial contains: Ceftriaxone Sodium IP eq. to Ceftriaxone 2000 mg Disodium Edetate IP 74 mg Sulbactam Sodium IP eq. to Sulbactam 1000 mg	1 Vial	M/s BDR Pharmaceuticals International Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd.	1036.60
14	4(xiv)	Ceftriaxone, Disodium Edetate & Sodium powder for solution for infusion	Each vial contains: Ceftriaxone Sodium IP eq. to Ceftriaxone 1000 mg Disodium Edetate IP 37 mg Sulbactam Sodium IP eq. to Sulbactam 500 mg	1 Vial	M/s BDR Pharmaceuticals International Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd.	515.57
15	4(xv)	Dapagliflozin, Glimepiride & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10 mg Glimepiride IP 1 mg Metformin Hydrochloride IP 1000 mg (as extended release)	1 Tablet	M/s Mascot Health Series Pvt. Ltd./ M/s USV Ltd.	11.95
16	4(xvi)	Dapagliflozin, Glimepiride & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 1000 mg (as extended release)	1 Tablet	M/s Mascot Health Series Pvt. Ltd./ M/s USV Ltd.	12.74

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
17	4(xvii)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 5 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Cipla Ltd.	11.83
18	4(xviii)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 5 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd.	11.83
19	4(xix)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Cipla Ltd.	19.01
20	4(xx)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg (as extended release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Micro Labs Ltd.	19.01
21	4(xxi)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Torrent Pharmaceuticals Ltd.	19.01
22	4(xxii)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd.	19.01

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
23	4(xxiii)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd.	19.01
24	4(xxiv)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 5 mg Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Torrent Pharmaceuticals Ltd.	15.84
25	4(xxv)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 5 mg Metformin Hydrochloride IP 1000 mg	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Jagsonpal Pharmaceuticals Ltd.	11.38
26	4(xxvi)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 5 mg Metformin Hydrochloride IP 1000 mg	1 Tablet	M/s Torrent Pharmaceuticals Ltd.	11.38
27	4(xxvii)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd.	18.10
28	4(xxviii)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin IH 12.5 mg Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Hetero Labs Ltd./ M/s Glenmark Pharmaceuticals Ltd.	18.10
29	4(xxix)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Torrent Pharmaceuticals Ltd.	18.10
30	4(xxx)	Empagliflozin & Metformin	Each film coated tablet contains: Empagliflozin 12.5 mg	1 Tablet	M/s Torrent Pharmaceuticals Ltd.	19.01

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
		Hydrochloride Tablets	Metformin Hydrochloride IP 1000 mg			
31	4(xxxi)	Fexofenadine Hydrochloride & Montelukast Tablets	Each film coated tablet contains: Fexofenadine Hydrochloride IP 120 mg Montelukast Sodium IP eq. to Montelukast 10 mg	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s German Remedies Pharmaceuticals Pvt. Ltd.	14.73
32	4(xxxii)	Glimepiride & Metformin Hydrochloride (SR) Tablets	Each uncoated bilayered tablet contains: Glimepiride IP 2 mg Metformin Hydrochloride IP (As sustained release form) 1000 mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s German Remedies Pharmaceuticals Pvt. Ltd.	11.58
33	4(xxxiii)	Linagliptin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Linagliptin 2.5 mg Metformin hydrochloride IP 500 mg	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Cadila Pharmaceuticals Ltd.	8.12
34	4(xxxiv)	Magaldrate, Dicyclomine Hydrochloride, Activated Dimethicone & Oxetacaine Oral Suspension	Each 5 ml contains: Magaldrate IP 480 mg Dicyclomine Hydrochloride IP 10 mg Activated Dimethicone IP 50 mg Oxetacaine IP 10 mg	1 ML	M/s Indoco Remedies Ltd.	0.53
35	4(xxxv)	Pantoprazole & Levosulpiride Capsules	Each hard gelatin capsule contains: Pantoprazole Sodium IP eq. to Pantoprazole 40 mg (as gastro-resistant tablet) Levosulpiride 75 mg (as uncoated sustained release tablet)	1 Capsule	M/s Akums Drugs & Pharmaceuticals Limited/ M/s Dr. Reddy's Laboratories Ltd.	17.89
36	4(xxxvi)	Polmacoxib & Paracetamol Tablets	Each uncoated tablet contains: Polmacoxib IH 2mg, Paracetamol IP 325mg	1 Tablet	M/s Hetero Labs Limited / M/s Hetero Healthcare Ltd.	14.75
37	4(xxxvii)	Povidone-Iodine Gargle	Povidone-Iodine IP 2% w/v (Available Iodine	1 ML	M/s Nanz Med Science Pharma	1.96

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
			0.2% w/v) Absolute Alcohol content 8.38% v/v		Pvt. Ltd. /M/s Troikaa Pharmaceuticals Ltd.	
38	4(xxxviii)	Telmisartan & Amlodipine Tablets	Each uncoated bilayered tablet contains: Telmisartan IP 80 mg, Amlodipine Besilate IP eq. to Amlodipine 5 mg	1 Tablet	M/s Windlas Biotech Ltd./ M/s Alkem Laboratories Ltd.	20.15
39	4(xxxix)	Mycophenolate Mofetil Oral Suspension	Each 5 ml of reconstituted suspension contains: Mycophenolate Mofetil IP 1 gm	Pack of 55gm	M/s Zydus Lifesciences Ltd.	2673.00
40	4(xl)	Acetylcysteine & Acebrophylline Tablets	Each film coated tablet contains: Acetylcysteine BP 600 mg Acebrophylline 100 mg	1 Tablet	M/s Pure and cure Healthcare Pvt. Ltd./ M/s Neon Laboratories Ltd.	15.09
41	4(xli)	Chlorhexidine Gluconate, Metronidazole & Lignocaine Hydrochloride Gel	Chlorhexidine gluconate solution IP eq. to Chlorhexidine 1 % w/w Metronidazole Benzoate IP eq. to Metronidazole 1 % w/w Lignocaine Hydrochloride IP 2 % w/w	1 GM	M/s Stedman Pharmaceuticals Pvt. Ltd.	3.65
42	4(xlii)	Sodium Alginate, Sodium Bicarbonate & Calcium carbonate Oral Liquid	Each 5 ml contains: Sodium Alginate IP 250 mg, Sodium Bicarbonate IP 133.5 mg, Calcium carbonate IP 80 mg	1 ML	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Aurobindo Pharma Ltd.	0.88 (Note 2)
43	4(xliii)	Dapagliflozin & Metoprolol (ER) Tablets	Each film coated bilayer tablet contains: Dapagliflozin propanediol USP eq. to Dapagliflozin 10mg Metoprolol Succinate IP 23.75 mg eq. to	1 Tablet	M/s Exemed Pharmaceuticals / M/s Ajanta Pharma Ltd.	15.83

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
			Metoprolol Tartrate 25 mg (extended release)			
44	4(xliv)	Dapagliflozin & Metoprolol (ER) Tablets	Each film coated bilayer tablet contains: Dapagliflozin propanediol USP eq. to Dapagliflozin 10mg Metoprolol Succinate IP 23.75 mg eq. to Metoprolol Tartrate 25 mg (extended release)	1 Tablet	M/s Exemed Pharmaceuticals /M/s Cipla Ltd.	15.96
45	4(xlv)	Paracetamol, Phenylephrine Hydrochloride, Caffeine & Diphenhydramine Tablets	Each film coated tablet contains: Paracetamol IP 500 mg, Phenylephrine Hydrochloride IP 5 mg Caffeine (Anhydrous) IP 30 mg Diphenhydramine Hydrochloride IP 25 mg	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Quality Bestochem Formulations (P) Ltd.	4.22
46	4(xlvi)	Paracetamol, Phenylephrine Hydrochloride, Caffeine & Diphenhydramine Tablets	Each film coated tablet contains: Paracetamol IP 500 mg, Phenylephrine Hydrochloride IP 5 mg Caffeine (Anhydrous) IP 30 mg Diphenhydramine Hydrochloride IP 25 mg	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Albert David Ltd.	4.22
47	4(xlvii)	Potassium Citrate, Magnesium Citrate & Vitamin B6 Oral Solution	Each 5 ml contains: Potassium Citrate IP 1100 mg Magnesium Citrate USP 375 mg Pyridoxine Hydrochloride (Vit.B6) IP 20 mg	1 ML	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd.	0.89
48	4(xlviii)	Sitagliptin, Dapagliflozin & Metformin Hydrochloride (Extended	Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg	1 Tablet	M/s Synokem Pharmaceuticals Ltd./ M/s Blue Cross Laboratories Pvt. Ltd.	11.70

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
		Release) Tablets	Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500 Mg (as Extended release)			
49	4(xlix)	Sitagliptin, Dapagliflozin & Metformin Hydrochloride (Extended Release) Tablets	Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000 Mg (as Extended release)	1 Tablet	M/s Synokem Pharmaceuticals Ltd./ M/s Blue Cross Laboratories Pvt. Ltd.	12.60
50	4(l)	Telmisartan, Chlorthalidon e & Metoprolol Succinate (ER) Tablets	Each film coated bilayer tablet contains: Telmisartan IP 40 mg Chlorthalidone IP 12.5 mg Metoprolol Succinate IP 47.5 mg eq. to Metoprolol Tartrate 50 mg (as extended- release form)	1 Tablet	M/s Mascot Health Series Pvt. Ltd./ M/s Alembic Pharmaceuticals Ltd.	13.70
51	4(li)	Telmisartan, Chlorthalidon e & Metoprolol Succinate (ER) Tablets	Each film coated bilayer tablet contains: Telmisartan IP 40 mg Chlorthalidone IP 6.25 mg Metoprolol Succinate IP 23.75 mg eq. to Metoprolol Tartrate 25 mg (as extended- release form)	1 Tablet	M/s Mascot Health Series Pvt. Ltd./ M/s Alembic Pharmaceuticals Ltd.	10.52
52	4(lii)	Telmisartan, Chlorthalidon e & Metoprolol Succinate (ER) Tablets	Each film coated bilayer tablet contains: Telmisartan IP 40 mg Chlorthalidone IP 6.25 mg	1 Tablet	M/s Mascot Health Series Pvt. Ltd./ M/s Alembic Pharmaceuticals Ltd.	10.73

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
			Metoprolol Succinate IP 47.5 mg eq. to Metoprolol Tartrate 50 mg (as extended-release form)			
53	4(liii)	Telmisartan, Chlorthalidone & Metoprolol Succinate (ER) Tablets	Each film coated bilayer tablet contains: Telmisartan IP 40 mg Chlorthalidone IP 12.5 mg Metoprolol Succinate IP 23.75 mg eq. to Metoprolol Tartrate 25 mg (as extended-release form)	1 Tablet	M/s Mascot Health Series Pvt. Ltd./ M/s Alembic Pharmaceuticals Ltd.	11.30
54	4(liv)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 5 mg Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Glensmith Labs Pvt. Ltd.	15.84
55	4(lv)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 5 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure and cure Healthcare Pvt. Ltd./ M/s Eris Lifesciences Ltd.	11.83
56	4(lvi)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 5 mg Metformin Hydrochloride IP 1000 mg	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Glensmith Labs Pvt. Ltd.	11.38
57	4(lvii)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Lifecare Formulations Pvt. Ltd./ M/s Primus Remedies Pvt. Ltd.	18.10
58	4(lviii)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Glensmith Labs Pvt. Ltd.	18.10

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
59	4(lix)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Lupin Ltd.	18.10
60	4(lx)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Jagsonpal Pharmaceuticals Ltd.	18.10
61	4(lxi)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure and cure Healthcare Pvt. Ltd./ M/s Eris Lifesciences Ltd.	19.01
62	4(lxii)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg	1 Tablet	M/s Lifecare Formulations Pvt. Ltd./ M/s Primus Remedies Pvt. Ltd.	19.01
63	4(lxiii)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Jagsonpal Pharmaceuticals Ltd.	19.01
64	4(lxiv)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg	1 Tablet	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Glensmith Labs Pvt. Ltd.	19.01
65	4(lxv)	Empagliflozin & Metformin Hydrochloride Tablets	Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg	1 Tablet	M/s Lupin Ltd.	19.01
66	4(lxvi)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 25 mg	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Intas	15.00

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
			Metformin Hydrochloride IP 1000 mg (as extended release)		Pharmaceuticals Ltd.	
67	4(lxvii)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 25 mg Metformin Hydrochloride IP 1000 mg (as extended release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Eris Lifesciences Ltd.	27.11
68	4(lxviii)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 25 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Torrent Pharmaceuticals Ltd.	27.00
69	4(lxix)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 25 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd.	27.11
70	4(lxx)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 25 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Cipla Ltd.	27.11
71	4(lxxi)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 25 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd.	27.11
72	4(lxxii)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 25 mg	1 Tablet	M/s Zydus Healthcare Ltd.	27.11

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
			Metformin Hydrochloride IP 1000 mg (Extended Release form)			
73	4(lxxiii)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 25 mg Metformin Hydrochloride IP 1000 mg (Extended Release form)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Alkem Laboratories Ltd.	27.11
74	4(lxxiv)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 10 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Cipla Ltd.	18.00
75	4(lxxv)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 10 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd.	22.96
76	4(lxxvi)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 10 mg Metformin Hydrochloride IP 1000 mg (as Extended Release)	1 Tablet	M/s Pure and cure Healthcare Pvt. Ltd./ M/s Eris Lifesciences Ltd.	22.96
77	4(lxxvii)	Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Empagliflozin 10 mg Metformin Hydrochloride IP 1000 mg (Extended Release form)	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Alkem Laboratories Ltd.	21.43
78	4(lxxviii)	Dapagliflozin, Gliclazide & Metformin Hydrochloride	Each film coated bilayered tablet contains: Dapagliflozin	1 Tablet	M/s Eris Lifesciences Ltd.	16.59

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
		sustained release) Tablets	propanediol USP eq. to Dapagliflozin 10mg Gliclazide IP 30 mg (as sustained release form) Metformin hydrochloride IP 500mg (as Sustained release form)			
79	4(lxxix)	Dapagliflozin, Gliclazide & Metformin Hydrochloride sustained release) Tablets	Each film coated bilayered tablet contains: Dapagliflozin propanediol USP eq. to Dapagliflozin 10mg Gliclazide IP 60 mg (as sustained release form) Metformin hydrochloride IP 500mg (as Sustained release form)	1 Tablet	M/s Eris Lifesciences Ltd.	20.03
80	4(lxxx)	Bilastine & Montelukast Oral Suspension	Each 5ml contains: Bilastine 10mg Montelukast Sodium IP eq. to Montelukast 4mg	1 ML	M/s Mascot Health Series Pvt. Ltd. / M/s Biological E. Limited	1.72

Note 1: The Authority noted that M/s Boehringer Ingelheim India Pvt. Ltd. (M/s BIPL) vide has filed representations through letters dated 7.3.2025 and 12.3.2025 against the retail prices of FDCs of 'Empagliflozin and Metformin' as recommended by MDC in its 66th meeting held on 3.3.2025 (minutes uploaded on 6.3.2025). M/s BIPL mentioned that the patent expiry date of Empagliflozin is 11.3.2025 and not 10.03.2025 as mentioned in the minutes of the 66th MDC meeting and M/s Cipla Limited is incorrectly mentioned as the license holder for patent for Empagliflozin. M/S BIPL also requested to recalculate the retail price considering the prices of Boehringer and co-marketers duly authorized by it i.e. by considering brands 'Jardiance', 'Gibtulo' and 'Cospiq' only.

The Authority noted that MDC has followed the methodology of reducing 50% of the patented component i.e. 'Empagliflozin' in line with Para 5 (3) (i) of DPCO 2013. Hence all brands with 1% or more market share including the brand of M/s Cipla Ltd. as appearing in Pharmarack database have been considered for working out the retail price of subject

FDC. Therefore, the Authority noted that the issues raised in the said representation including date of patent expiry do not impact the prices recommended by MDC.

Note 2: The Authority directed that the price may be notified on per ml basis as per practice.

5. Agenda item no. 5: Status of implementation of Review order cases

5.1 Noted.

6. Agenda item no. 6: Minutes of 66th meeting of Multidisciplinary Committee of Experts held on 3.3.2025

6.1 Noted.

7. Agenda item no. 7: Retail price fixation of Each uncoated dispersible tablet contains Methylprednisolone IP 4mg for M/s J.K. Printpack (Pharma Division) (Manufacturer) & M/s Biological E. Ltd. (Marketer) (F.No. 3992)

7.1 The Authority noted that M/s Biological E. Ltd. has applied for retail price fixation of each uncoated dispersible tablet containing 'Methylprednisolone IP 4 mg'. The company has furnished approval of DCGI for 'Methylprednisolone' i.e. without mentioning the strength and dosage form. The Authority noted the deliberation held in the MDC and directed that the applicant may be asked to submit the approval of the DCGI for the applied formulation wherein the strength of the formulation is also mentioned.

8. Agenda item no. 8: Form -IV intimation for discontinuation of 4 scheduled formulation viz., (i) Urografin 76%-20ml (ii) Urografin 76%-50ml (iii) Urografin 76%-100ml and (iv) Urografin 60%-20ml by Bayer Zydus Pharma under Para 21(2) of DPCO, 2013


8.1 The Authority deliberated upon the matter and noted the re-invocation of Para 3 of DPCO, 2013 on M/s Bayer Zydus Pharma in r/o Urografin 76%-20ml, Urografin 76%-50ml, Urografin 76%-100ml, and Urografin 60%-20ml, effective till 28.02.2026. The Authority also noted that the company has been directed to comply with the directions as issued vide letter dated 28.02.2024.

9. Agenda item no. 9: Wholesale Price Index as per Para 16 of DPCO, 2013 to be applicable from 1.4.2025

9.1 The Authority noted that DPIIT, Ministry of Commerce and Industry, Government of India has confirmed the monthly final Wholesale Price Indices (WPI) of all commodities for the year 2023 and 2024 vide O.M. OEA-11025(13)/18/2017-WPD-Part (256) dated 18.3.2025. The Authority deliberated upon the matter in detail and as per provisions of

DPCO, 2013 approved the WPI @ (+) 1.74028% to be applicable on scheduled formulations w.e.f. 1.4.2025. The Authority further decided to issue an Office Memorandum intimating the WPI to be applicable w.e.f. 1.4.2025 and to issue notification (s) for revised ceiling price of scheduled formulations based on WPI @ (+) 1.74028% to be effective from 1.4.2025.

The meeting ended with a vote of thanks to the Chair and all the participants in the meeting.


26/8/2025
(Dr. Vinod Kotwal)
Member Secretary